{"id":"biologic-dmards","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Malignancy risk"},{"rate":null,"effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL2108852","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Biologic disease-modifying antirheumatic drugs (DMARDs) work by targeting key components of the immune system, such as TNF-alpha, IL-6, T-cell co-stimulation, or B-cells, to suppress the inflammatory cascade driving autoimmune disease. By blocking these specific molecular targets, they reduce joint inflammation, prevent tissue damage, and improve clinical outcomes in conditions like rheumatoid arthritis. This class includes TNF inhibitors, IL-6 inhibitors, T-cell co-stimulators, and B-cell depleting agents.","oneSentence":"Biologic DMARDs are immunosuppressive agents that target specific immune pathways to reduce inflammation and slow disease progression in autoimmune conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:21:06.540Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other autoimmune inflammatory conditions (specific agents vary)"}]},"trialDetails":[{"nctId":"NCT07489326","phase":"","title":"The SetPoint System Safety & Performance Post-Approval Study","status":"NOT_YET_RECRUITING","sponsor":"SetPoint Medical Corporation","startDate":"2026-04-15","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT07286058","phase":"PHASE3","title":"Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-03-11","conditions":"Psoriatic Arthritis","enrollment":1182},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07436494","phase":"","title":"Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs","status":"COMPLETED","sponsor":"Bursa City Hospital","startDate":"2020-10-15","conditions":"COVID-19, Anxiety, Rheumatic Diseases","enrollment":200},{"nctId":"NCT06641076","phase":"PHASE3","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug","status":"ACTIVE_NOT_RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-10-15","conditions":"Arthritis, Psoriatic","enrollment":960},{"nctId":"NCT07417995","phase":"","title":"A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Royal United Hospitals Bath NHS Foundation Trust","startDate":"2026-03","conditions":"Psoriasis Arthritis","enrollment":400},{"nctId":"NCT06382051","phase":"NA","title":"Modifying PEST for Psoriatic Arthritis Screening","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-01-23","conditions":"Plaque Psoriasis, Psoriatic Arthritis","enrollment":502},{"nctId":"NCT06764693","phase":"","title":"An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-01-31","conditions":"Psoriatic Arthritis","enrollment":1200},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT06276998","phase":"PHASE3","title":"A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2023-12-12","conditions":"Rheumatoid Arthritis","enrollment":430},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT04908202","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-13","conditions":"Psoriatic Arthritis","enrollment":670},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":"Rheumatic Diseases","enrollment":129},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT05572567","phase":"","title":"Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-10","conditions":"Arthritis, Rheumatoid","enrollment":1972},{"nctId":"NCT06718569","phase":"","title":"Pain in Inflammatory Joint Diseases","status":"NOT_YET_RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2025-08","conditions":"Arthritis, Arthritis, Juvenile Idiopathic, Arthritis,Rheumatoid","enrollment":350},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT06945666","phase":"PHASE4","title":"A Study of Iguratimod in Combination With Tofacitinib in RA Patients","status":"NOT_YET_RECRUITING","sponsor":"Jie Chang","startDate":"2025-08-01","conditions":"Rheumatoid Arthritis (RA","enrollment":200},{"nctId":"NCT01247766","phase":"","title":"Safety Study of Abatacept to Treat Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12-31","conditions":"Rheumatoid Arthritis","enrollment":6367},{"nctId":"NCT03531073","phase":"","title":"Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-04-18","conditions":"Psoriatic Arthritis","enrollment":446},{"nctId":"NCT01932372","phase":"","title":"Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07-26","conditions":"Rheumatoid Arthritis","enrollment":9968},{"nctId":"NCT05291819","phase":"NA","title":"Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2022-03-14","conditions":"Psoriatic Arthritis","enrollment":202},{"nctId":"NCT04748939","phase":"PHASE4","title":"Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT","status":"NOT_YET_RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2025-01","conditions":"Herpes Zoster","enrollment":140},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT06417138","phase":"","title":"Comparative Effectiveness of Different Drugs Used to tr€at Patients in Rheumatoid Arthritis Saudi Database (RASD)\"","status":"RECRUITING","sponsor":"Umm Al-Qura University","startDate":"2023-12-15","conditions":"Rheumatoid Arthritis RA","enrollment":800},{"nctId":"NCT06306339","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)","status":"UNKNOWN","sponsor":"ImmuneMed, Inc.","startDate":"2024-03","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05545020","phase":"PHASE2, PHASE3","title":"Trivalent Chromium Treatment for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-12-25","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT04749160","phase":"","title":"Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-06-04","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT03970837","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-06-05","conditions":"Arthritis, Rheumatoid","enrollment":1764},{"nctId":"NCT06020144","phase":"PHASE3","title":"A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs","status":"UNKNOWN","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-11-15","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT01844518","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-30","conditions":"Active Polyarticular Juvenile Idiopathic Arthritis","enrollment":219},{"nctId":"NCT05767801","phase":"","title":"Synovial Tissue and Blood Signature of Rheumatoid Arthritis Patients With Disease Flare After Treatment Discontinuation for Sustained Remission.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-11-15","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT05767814","phase":"","title":"Optimization of Psoriatic and Seronegative Rheumatoid Arthritis Patients Selection and Treatment Outcomes of Biologic Therapies.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-10-03","conditions":"Psoriatic Arthritis, Rheumatoid Arthritis","enrollment":135},{"nctId":"NCT05683769","phase":"","title":"microRNA in Erosive Hand Osteoarthritis and Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Siena","startDate":"2018-09-01","conditions":"Erosive Osteoarthritis, Psoriatic Arthritis","enrollment":150},{"nctId":"NCT02706847","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-15","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT05540743","phase":"PHASE4","title":"Biologic Therapy in Pediatric JIA Uveitis","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2022-07-01","conditions":"Juvenile Idiopathic Arthritis Associated Uveitis","enrollment":250},{"nctId":"NCT04434885","phase":"","title":"Axial Involvement in Psoriatic Arthritis Cohort","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2021-07-01","conditions":"Psoriatic Arthritis","enrollment":400},{"nctId":"NCT05165771","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2022-07","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01146652","phase":"PHASE3","title":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06-21","conditions":"Rheumatoid Arthritis","enrollment":2023},{"nctId":"NCT05267431","phase":"","title":"Outcomes of Biological Therapy on Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-06","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT01490450","phase":"PHASE2","title":"Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-12","conditions":"Arthritis, Psoriatic","enrollment":165},{"nctId":"NCT03131661","phase":"","title":"A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2017-06-09","conditions":"Spondyloarthritis, Axial and Peripheral","enrollment":351},{"nctId":"NCT03011242","phase":"","title":"DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2017-01-11","conditions":"Psoriatic Arthritis","enrollment":47},{"nctId":"NCT05001672","phase":"PHASE4","title":"The Efficacy of Prophylactic TAF for HBsAg-positive Patients Receiving bDMARDs","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2021-08-15","conditions":"HBV, Inflammatory Arthritis","enrollment":108},{"nctId":"NCT04973787","phase":"","title":"The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2020-08-01","conditions":"Axial Spondyloarthritis, Arthritis, Rheumatoid","enrollment":90},{"nctId":"NCT02627768","phase":"","title":"A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2015-12-17","conditions":"Psoriatic Arthritis","enrollment":991},{"nctId":"NCT03964649","phase":"","title":"Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-01","conditions":"Arthritis, Rheumatoid","enrollment":7308},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT03682705","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":242},{"nctId":"NCT04821206","phase":"","title":"PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors","status":"UNKNOWN","sponsor":"Liga Panamericana de Asociaciones de Reumatologia (PANLAR)","startDate":"2021-03-01","conditions":"Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondyloarthritis","enrollment":3000},{"nctId":"NCT04483687","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2020-12","conditions":"Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT04483700","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2020-12","conditions":"Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT01387802","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06-29","conditions":"Ankylosing Spondylitis","enrollment":722},{"nctId":"NCT01602302","phase":"PHASE4","title":"Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01559038","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02-16","conditions":"Psoriatic Arthritis","enrollment":483},{"nctId":"NCT03073109","phase":"","title":"Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-03-15","conditions":"Arthritis, Rheumatoid","enrollment":170},{"nctId":"NCT02557100","phase":"PHASE4","title":"Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-19","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT04499001","phase":"","title":"Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis With Subcutaneous Biologic DMARDs","status":"UNKNOWN","sponsor":"Hôpital Cochin","startDate":"2019-10-01","conditions":"Arthritis, Rheumatoid, Spondyloarthritis, Biological Therapy","enrollment":60},{"nctId":"NCT01095393","phase":"","title":"National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09-01","conditions":"Rheumatoid Arthritis","enrollment":12500},{"nctId":"NCT04472390","phase":"","title":"Study of Tapering and Discontinuing Biological DMARDs in Rheumatoid Arthritis Patients","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-12-03","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT02349295","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12-31","conditions":"Psoriatic Arthritis","enrollment":363},{"nctId":"NCT04449224","phase":"","title":"Comparative Effectiveness of Targeted Therapy in RA Patients","status":"UNKNOWN","sponsor":"Hanyang University","startDate":"2020-04-27","conditions":"Rheumatoid Arthritis","enrollment":506},{"nctId":"NCT02584855","phase":"PHASE3","title":"A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-09-14","conditions":"Psoriatic Arthritis","enrollment":394},{"nctId":"NCT04139954","phase":"","title":"Observational Registry of Patients With Rheumatoid Arthritis /Spondyloarthritis Using Biological or Targeted Synthetic DMARDs","status":"UNKNOWN","sponsor":"Turkish League Against Rheumatism","startDate":"2019-02-01","conditions":"Rheumatoid Arthritis, Spondyloarthritis","enrollment":1400},{"nctId":"NCT03330769","phase":"","title":"Ultrasound in Psoriatic Arthritis Treatment","status":"UNKNOWN","sponsor":"University of Cagliari","startDate":"2017-02-03","conditions":"Arthritis, Psoriatic, Ultrasonography, Minimal Disease, Residual","enrollment":250},{"nctId":"NCT03908086","phase":"","title":"Bloodstream Infections in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sabine Dieperink","startDate":"1996-12-31","conditions":"Rheumatoid Arthritis, Staphylococcus Aureus Bacteremia","enrollment":6000000},{"nctId":"NCT01695239","phase":"PHASE3","title":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Psoriasis, Arthritic","enrollment":417},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT03327454","phase":"","title":"Benepali® PEN Patient Satisfaction Survey","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-08-10","conditions":"Rheumatoid Arthritis, Spondyloarthropathies","enrollment":500},{"nctId":"NCT01407419","phase":"NA","title":"The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population","status":"COMPLETED","sponsor":"CorEvitas","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":538},{"nctId":"NCT02832297","phase":"NA","title":"Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care","status":"UNKNOWN","sponsor":"Crescendo Bioscience","startDate":"2016-06","conditions":"Arthritis, Rheumatoid","enrollment":318},{"nctId":"NCT03508713","phase":"","title":"Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-05-13","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT01034397","phase":"PHASE4","title":"A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT00810277","phase":"PHASE3","title":"A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-30","conditions":"Rheumatoid Arthritis","enrollment":14},{"nctId":"NCT02590562","phase":"","title":"An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-12-31","conditions":"Rheumatoid Arthritis","enrollment":808},{"nctId":"NCT01362062","phase":"","title":"Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10-26","conditions":"Rheumatoid Arthritis","enrollment":110},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT02019901","phase":"NA","title":"GotNet Study, The Gothenburg Nurse-led Tight Control Study","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT00443651","phase":"PHASE3","title":"A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-01","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT00975130","phase":"PHASE3","title":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":3366},{"nctId":"NCT03082573","phase":"PHASE4","title":"Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel","status":"UNKNOWN","sponsor":"Iraj Sabahi Research Inc.","startDate":"2017-03-03","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT01033656","phase":"PHASE2","title":"Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"2005-12","conditions":"Adult-Onset Still's Disease","enrollment":23},{"nctId":"NCT01791205","phase":"","title":"ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":304},{"nctId":"NCT01088321","phase":"","title":"Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-03","conditions":"Rheumatoid Arthritis","enrollment":81332},{"nctId":"NCT01617005","phase":"","title":"A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT02011334","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07","conditions":"Rheumatoid Arthritis","enrollment":285},{"nctId":"NCT01878318","phase":"PHASE4","title":"A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01149057","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":145},{"nctId":"NCT01162421","phase":"PHASE4","title":"A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":649,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rimicade, adalimumab"],"phase":"marketed","status":"active","brandName":"biologic DMARDs","genericName":"biologic DMARDs","companyName":"Kasr El Aini Hospital","companyId":"kasr-el-aini-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biologic DMARDs are immunosuppressive agents that target specific immune pathways to reduce inflammation and slow disease progression in autoimmune conditions. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions (specific agents vary).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}